Skip to content

Merck & Company Inc Price, Chart & Factor Exposure

Free Data & Analytics Access

Latest earnings: October 29, 2026 results vs estimates

Merck & Company Inc · E.MRK.NYSE · United States
Use symbol E.MRK.NYSE in our API & Excel add-in to retrieve this data ↓
146.33
(+0.04%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 50%
Trend 100%
Bubble Risk LOW
Realised Volatility (20D) 33.99%

Merck & Company Inc Forecast

Merck & Company Inc short-term momentum is positive (up over 3 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 34.0% a year, a typical one-standard-deviation range is 139.32–153.34 over a week, 131.97–160.69 over a month and 96.60–196.06 over a year. (Signals as of 1 Nov 2026.)

Merck & Company Inc Price Chart

MacroFinance.ai

Merck & Company Inc Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
Merck & Company Inc
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Merck & Company Inc
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Merck & Company Inc
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Merck & Company Inc
P/E
148.12x
Stretched vs own history
QoQ +24.6%
YoY +1,054.5%
now 148.119613.09 low149.57 high
ⓘP/E As of 22 Nov 2026.See Merck & Company Inc returns when P/E looked like now →Opens Return analysis with the filter P/E within ±5% of today
Merck & Company Inc
P/S
5.40x
Stretched vs own history
QoQ −4.8%
YoY +42.0%
now 5.39863.88 low5.67 high
ⓘP/S As of 22 Nov 2026.See Merck & Company Inc returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Merck & Company Inc
P/B
8.09x
Stretched vs own history
QoQ −10.0%
YoY +71.8%
now 8.09344.8 low8.99 high
ⓘP/B As of 22 Nov 2026.See Merck & Company Inc returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
Merck & Company Inc
EV/EBITDA
34.52x
Stretched vs own history
QoQ +12.6%
YoY +254.4%
now 34.51639.92 low34.82 high
ⓘEV/EBITDA As of 22 Nov 2026.See Merck & Company Inc returns when EV/EBITDA looked like now →Opens Return analysis with the filter EV/EBITDA within ±5% of today
Merck & Company Inc
EV/Sales
6.05x
Stretched vs own history
QoQ −5.0%
YoY +45.4%
now 6.05434.24 low6.37 high
ⓘEV/Sales As of 22 Nov 2026.See Merck & Company Inc returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Merck & Company Inc
FCF Yield
4.1%
Mid-range vs own history
QoQ −4.7%
YoY −24.0%
now 4.05854.01 low5.24 high
ⓘFCF Yield As of 22 Nov 2026.See Merck & Company Inc returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
Merck & Company Inc
Earnings Yield
0.7%
Weak vs own history
QoQ −19.8%
YoY −91.3%
now 0.67510.67 low7.64 high
ⓘEarnings Yield As of 22 Nov 2026.See Merck & Company Inc returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Merck & Company Inc
Dividend Yield
2.3%
Weak vs own history
QoQ +4.6%
YoY −30.7%
now 2.30252.2 low3.26 high
ⓘDividend Yield As of 22 Nov 2026.See Merck & Company Inc returns when Dividend Yield looked like now →Opens Return analysis with the filter Dividend Yield within ±5% of today
Merck & Company Inc
Market Cap
$363.3B
Highest in 5 years
QoQ −3.7%
YoY +48.8%
now 363337.39249,101 low377,104 high
ⓘMarket Cap As of 22 Nov 2026.See Merck & Company Inc returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Merck & Company Inc
Net Debt
$44.1B
High vs own history
QoQ −5.6%
YoY +90.5%
now 4412723,160 low46,765 high
ⓘNet Debt As of 22 Nov 2026.See Merck & Company Inc returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Merck & Company Inc
Net Debt / EBITDA
3.74x
High vs own history
QoQ +10.5%
YoY +343.1%
now 3.7380.84 low3.74 high
ⓘNet Debt / EBITDA As of 22 Nov 2026.See Merck & Company Inc returns when Net Debt / EBITDA looked like now →Opens Return analysis with the filter Net Debt / EBITDA within ±5% of today
Merck & Company Inc
Current Ratio
1.35x
Mid-range vs own history
QoQ +2.2%
YoY −18.6%
now 1.35211.3 low1.66 high
ⓘCurrent Ratio As of 22 Nov 2026.See Merck & Company Inc returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Merck & Company Inc
Quick Ratio
1.14x
Mid-range vs own history
QoQ +3.6%
YoY −20.8%
now 1.13811.06 low1.44 high
ⓘQuick Ratio As of 22 Nov 2026.See Merck & Company Inc returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Merck & Company Inc
Interest Coverage
3.18x
Weak vs own history
QoQ −22.0%
YoY −82.3%
now 3.18413.18 low17.98 high
ⓘInterest Coverage As of 22 Nov 2026.See Merck & Company Inc returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
Merck & Company Inc
Debt / Equity
1.20x
High vs own history
QoQ −6.8%
YoY +50.1%
now 1.19790.8 low1.29 high
ⓘDebt / Equity As of 22 Nov 2026.See Merck & Company Inc returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
Merck & Company Inc
Piotroski F-Score
4
Weak vs own history
QoQ 0.0%
YoY −42.9%
now 44 low7 high
ⓘPiotroski F-Score As of 22 Nov 2026.See Merck & Company Inc returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
Merck & Company Inc
Altman Z-Score
3.93
Mid-range vs own history
QoQ −2.5%
YoY +0.3%
now 3.93423.63 low4.39 high
ⓘAltman Z-Score As of 22 Nov 2026.See Merck & Company Inc returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  19 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  21 members-only factors: Sloan Accruals, Cash-Earnings Gap, Beneish M-Score, Days Sales in Receivables Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Merck & Company Inc, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Merck & Company Inc fundamentals: income statement, balance sheet & cash flow

Merck & Company Inc reported revenue of $64.93bn and net income of $18.25bn in FY2025, the year ended 31 December 2025 — revenue up 1.2% and net income up 6.6% on the prior year. Free cash flow was $12.36bn. These figures are as reported in the filings, not restated: 41 fiscal years and 165 quarters of history, back to December 1985. 173 FINRA short-interest settlements are published alongside them, back to June 2019.

Revenue (FY2025)
$64.93bn
+1.2%
Net income
$18.25bn
+6.6%
Gross margin
71.98%
Free cash flow
$12.36bn
-31.7%
Net debt
$35.97bn
Shares short (30 Oct 2026)
26.60m
2.36 days to cover
Merck & Company Inc income statement, annual, as reported · USD billions unless stated
USD billionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue64.9364.1760.1259.2848.70
Cost of revenue18.2015.1916.1317.4113.63
Gross profit46.7348.9843.9941.8735.08
Research & development12.5117.9430.5313.5512.25
Operating income23.4920.222.9518.2813.20
EBITDA28.2625.716.9121.3217.90
Interest expense1.361.271.150.960.81
Pre-tax income21.0719.941.8916.4413.88
Income tax2.802.801.511.921.52
Net income18.2517.120.3714.5213.05

Download Merck & Company Inc fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.MRK.NYSE&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 41 fiscal years and 165 quarters, the filing vintages behind each number and API access.
Create free account

Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.

Research on Merck & Company Inc

Recent MacroFinance research reports referencing Merck & Company Inc, newest first.

Browse all financial research →

Merck & Company Inc Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Merck & Company Inc; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

Statistical Distribution of Returns

Plus

How Merck & Company Inc’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Merck & Company Inc behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Merck & Company Inc (United States)

Merck & Company Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on Merck & Company Inc

Frequently asked questions

What is Merck & Company Inc?
Merck & Company Inc is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Merck & Company Inc price?
The latest close is 146.33 (1 Nov 2026), +0.04% on the day. The price at the top of the page refreshes during the trading day.
Is Merck & Company Inc in an uptrend?
As of 1 Nov 2026, short-term momentum is positive (3 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (8 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Merck & Company Inc?
20-day realised volatility is 34.0% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 9.8% over a month and 4.8% over a week.
What factors affect Merck & Company Inc?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Merck & Company Inc, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Merck & Company Inc?
58 backtested tactical asset allocation strategies trade Merck & Company Inc through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Merck & Company Inc returns analysed?
The Statistical Distribution of Returns section shows the distribution of Merck & Company Inc daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Merck & Company Inc historical data?
In the Free historical data section of this page: the last 10 years of Merck & Company Inc daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Merck & Company Inc historical data (last 10 years)

Browse or instantly download the last 10 years of Merck & Company Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.MRK.NYSE&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-20133.72
2026-11-19132.81
2026-11-18137.78
2026-11-17143.37
2026-11-16144.46
2026-11-13147.76
2026-11-12146.95
2026-11-11147.18
2026-11-10148.05
2026-11-09148.76
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.